Pembrolizumab and chemoradiotherapy for muscle invasive bladder cancer: The ANZUP 1502 PCR-MIB trial.
Andrew James Weickhardt, Farshad Foroudi, Shomik Sengupta, Laura Galletta, Alan Herschtal, Peter S Grimison, Nitya Patanjali, Siobhan Ng, Colin Tang, Robert Goodwin, Elizabeth J Hovey, Tom Jarvis, Colin Chen, Shahneen Kaur Sandhu, Keen Hun Tai, Nathan Lawrentschuk, Ian D Davis
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
TPS531 Background: Pembrolizumab leads to responses in ~20% of metastatic bladder cancer patients. Irradiation of bladder cancer cells in-vitro and in-vivo leads to upregulation of PD-L1, and in immunocompetent mouse models blockade of PD-L1 leads to delayed tumour growth following irradiation. Randomised data from PACIFIC trial in NSCLC shows the addition of PD-L1 inhibition to chemoradiation significantly prolongs PFS. A trial of chemoradiotherapy with pembrolizumab will assess safety and synergy of the combination in localised bladder cancer. Methods: This pilot study enrols patients with maximally resected non-metastatic muscle invasive bladder cancer, who either wish for bladder preser..View full abstract